Quantum-Si initiated with bullish view at H.C. Wainwright, here’s why

H.C. Wainwright analyst Swayampakula Ramakanth initiated coverage of Quantum-Si with a Buy rating and $3 price target. Quantum-Si is a commercial stage medical device company that has developed a novel platform utilizing proprietary semiconductor and novel surface chemistry to conduct next generation protein sequencing, the analyst tells investors in a research note. The firm believes the shares are undervalued and an attractive opportunity for a long-term investor.